» Articles » PMID: 37325521

Co-delivery of a Tumor Microenvironment-responsive Disulfiram Prodrug and CuO Nanoparticles for Efficient Cancer Treatment

Overview
Journal Nanoscale Adv
Specialty Biotechnology
Date 2023 Jun 16
PMID 37325521
Authors
Affiliations
Soon will be listed here.
Abstract

Disulfiram (DSF) has been used as a hangover drug for more than seven decades and was found to have potential in cancer treatment, especially mediated by copper. However, the uncoordinated delivery of disulfiram with copper and the instability of disulfiram limit its further applications. Herein, we synthesize a DSF prodrug using a simple strategy that could be activated in a specific tumor microenvironment. Poly amino acids are used as a platform to bind the DSF prodrug through the B-N interaction and encapsulate CuO nanoparticles (NPs), obtaining a functional nanoplatform Cu@P-B. In the acidic tumor microenvironment, the loaded CuO NPs will produce Cu and cause oxidative stress in cells. At the same time, the increased reactive oxygen species (ROS) will accelerate the release and activation of the DSF prodrug and further chelate the released Cu to produce the noxious copper diethyldithiocarbamate complex, which causes cell apoptosis effectively. Cytotoxicity tests show that the DSF prodrug could effectively kill cancer cells with only a small amount of Cu (0.18 μg mL), inhibiting the migration and invasion of tumor cells. and experiments have demonstrated that this functional nanoplatform could kill tumor cells effectively with limited toxic side effects, showing a new perspective in DSF prodrug design and cancer treatment.

Citing Articles

Recent advances in copper homeostasis-involved tumor theranostics.

Ren X, Luo X, Wang F, Wan L, Wang X, Xiong J Asian J Pharm Sci. 2024; 19(5):100948.

PMID: 39474127 PMC: 11513462. DOI: 10.1016/j.ajps.2024.100948.

References
1.
Arruebo M, Vilaboa N, Saez-Gutierrez B, Lambea J, Tres A, Valladares M . Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2013; 3(3):3279-330. PMC: 3759197. DOI: 10.3390/cancers3033279. View

2.
Ren L, Feng W, Shao J, Ma J, Xu M, Zhu B . Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting. Theranostics. 2020; 10(14):6384-6398. PMC: 7255023. DOI: 10.7150/thno.45558. View

3.
Luan M, Chang J, Pan W, Chen Y, Li N, Tang B . Simultaneous Fluorescence Visualization of Epithelial-Mesenchymal Transition and Apoptosis Processes in Tumor Cells for Evaluating the Impact of Epithelial-Mesenchymal Transition on Drug Efficacy. Anal Chem. 2018; 90(18):10951-10957. DOI: 10.1021/acs.analchem.8b02494. View

4.
Shao S, Zhou Q, Si J, Tang J, Liu X, Wang M . A non-cytotoxic dendrimer with innate and potent anticancer and anti-metastatic activities. Nat Biomed Eng. 2019; 1(9):745-757. DOI: 10.1038/s41551-017-0130-9. View

5.
Fasehee H, Dinarvand R, Ghavamzadeh A, Esfandyari-Manesh M, Moradian H, Faghihi S . Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations. J Nanobiotechnology. 2016; 14:32. PMC: 4839071. DOI: 10.1186/s12951-016-0183-z. View